Comprehensive Analysis of Allelic, Cellular and Molecular Heterogeneity in Human 3-Dimensional Cardiac Microtissues with MYH7 Mutations
Comprehensive Analysis of Allelic, Cellular and Molecular Heterogeneity in Human 3-Dimensional Cardiac Microtissues with MYH7 Mutations
批准号:
9983170
负责人:
John Travis Hinson
金额:
$53.99万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-01 至 2022-06-30
关键词:
3-DimensionalATAC-seqActinsAllelesArchitectureArginineBindingBiological AssayBiological MarkersBiomimeticsCRISPR/Cas technologyCardiacCardiac MyocytesCell LineCellsChromatinComputing MethodologiesConsumptionDataDiseaseDisease modelEngineeringEpigenetic ProcessFutureGene ExpressionGene Expression ProfileGene MutationGene TargetingGenesGeneticGenetic TranscriptionGenotype-Tissue Expression ProjectGlutamineGoalsHeart failureHeterogeneityHigh-Throughput Nucleotide SequencingHumanHuman EngineeringHypertrophic CardiomyopathyImageImmunofluorescence ImmunologicIndividualInheritedKineticsKnock-outKnowledgeLaboratoriesLeadLinkLocationMechanicsMetabolicMethionineMitochondriaMitochondrial ProteinsModelingMolecularMolecular MotorsMutationMyocardiumMyofibrilsMyosin Heavy ChainsNuclearPathogenesisPathologicPathologyPathway AnalysisPatientsPatternPhenotypePrevalenceProteinsRNA analysisRegulatory ElementResearchResolutionRiskRoleSarcomeresSecondary toStressStructureSymptomsTherapeuticThree-dimensional analysisTissuesTranscriptTransposaseTreatment EfficacyValineVariantbeta-Myosincell typecohortdisease heterogeneitygenetic variantgenomic toolsheart dimension/sizeheart functionin vivoinduced pluripotent stem cellinsightnew therapeutic targetnovelprogramsresponsesingle-cell RNA sequencingstem cell differentiationstem cell modelsudden cardiac deaththerapeutic developmenttherapeutic targettranscriptometranscriptome sequencingtreatment response
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Hypertrophic cardiomyopathy (HCM) patients are at risk for sudden cardiac death and progressive heart
failure (HF), and there are no effective therapeutics, due in part to our limited genetic understanding of HCM
pathogenesis. There are critical gaps in our current knowledge of the molecular mechanisms that link specific
mutations in the beta myosin heavy chain gene (MYH7) to pathological thickening of the heart muscle that is
associated with HCM. Our long-term goals are to utilize genomic tools combined with 3-dimensional cardiac
microtissues derived from human induced pluripotent stem cells to interrogate mechanisms of HCM secondary
to specific MYH7 variants, and to utilize these insights to identify new disease biomarkers and therapeutic targets
for specific HCM patients.
Our previous studies identified that two HCM-associated MYH7 variants, arginine 403 to glutamine and
valine 606 to methionine that are located in the actin-binding domain of beta myosin heavy chain protein (MHC-
β), generate increased microtissue contraction force with associated abnormalities in contraction kinetics.
Studies by others have indicated that MYH7 variants located in distinct structural domains of MHC-β cause
distinct phenotypes. These results lead to our central hypothesis that HCM is a heterogeneous disorder, in which
patient symptoms and therapeutic responses are dependent on the location of the causative MYH7 variant(s)
within the gene and on cell-type specific transcriptional and epigenetic programs, which initiate from
abnormalities in contractile function. Guided by our comprehensive preliminary data, we propose to pursue three
Specific Aims to determine multi-scale insights into HCM pathogenesis: (1) to characterize functional
consequences of MYH7 variants localized to the actin-binding, ATP-binding and converter domains of MHC-
β, (2) to identify cell type-specific transcriptional and epigenetic mechanisms of HCM in microtissues using paired
single-cell RNA-seq and ATAC-seq and (3) to interrogate the function of C1ORF105, a nuclear-encoded
mitochondrial protein that is associated with HCM and is specifically expressed in human cardiomyocytes.
In summary, the execution of these aims will provide a more precise understanding of the functional role
of MYH7 variant localization, generate novel cell-type specific and molecular mechanisms of HCM and identify
critical molecular linkages between sarcomere and mitochondrial function that will broadly impact the field of
HCM and heart failure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SCGE Disease Models Studies Supplement: Cardioediting Ttntvs in a humanized mouse model
-
批准号:10619106
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2022
-
负责人:John Travis Hinson
-
依托单位:
Human cardiac microtissues with innate immune sensing to study adverse consequences of genome editing
-
批准号:10463658
-
项目类别:
-
资助金额:$73.7万
-
财政年份:2019
-
负责人:John Travis Hinson
-
依托单位:
Human cardiac microtissues with innate immune sensing to study adverse consequences of genome editing
-
批准号:9810840
-
项目类别:
-
资助金额:$75.23万
-
财政年份:2019
-
负责人:John Travis Hinson
-
依托单位:
Human cardiac microtissues with innate immune sensing to study adverse consequences of genome editing
-
批准号:10245264
-
项目类别:
-
资助金额:$73.8万
-
财政年份:2019
-
负责人:John Travis Hinson
-
依托单位:
Comprehensive Analysis of Allelic, Cellular and Molecular Heterogeneity in Human 3-Dimensional Cardiac Microtissues with MYH7 Mutations
-
批准号:10210431
-
项目类别:
-
资助金额:$53.99万
-
财政年份:2018
-
负责人:John Travis Hinson
-
依托单位:
Metabolic and developmental regulation by AMPK in PRKAG2-associated cardiomyopathy
-
批准号:9182902
-
项目类别:
-
资助金额:$17.71万
-
财政年份:2014
-
负责人:John Travis Hinson
-
依托单位:
Metabolic and developmental regulation by AMPK in PRKAG2-associated cardiomyopathy
-
批准号:9264223
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2014
-
负责人:John Travis Hinson
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位: